BioCentury
ARTICLE | Company News

Roche returning rights to Inovio's HBV vaccine

August 3, 2016 7:00 AM UTC

Inovio Pharmaceuticals Inc. (NASDAQ:INO) said Roche (SIX:ROG; OTCQX:RHHBY) is terminating a 2013 deal and is returning exclusive, worldwide rights to Inovio's hepatitis B vaccine INO-1800.

Inovio expects data in 2H17 from an open-label Phase I study of the synthetic DNA vaccine encoding a recombinant consensus plasmid from genotype A through E of the hepatitis B core antigen (HBcAg). The study is evaluating INO-1800 alone or in combination with INO-9112, an interleukin-12 (IL-12)-based immune activator, to treat HBV. ...